<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-27T10:19:51Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/94146" metadataPrefix="mods">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/94146</identifier><datestamp>2025-03-18T14:17:07Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
   <mods:name>
      <mods:namePart>Santamaría-Aguirre, Javier</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Jacho, Daniela</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Méndez, Miguel A.</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Poveda, Ana</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Carrión Herrero, Francisco Javier</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Fanarraga, Mónica L.</mods:namePart>
   </mods:name>
   <mods:extension>
      <mods:dateAvailable encoding="iso8601">2024-01-19T18:07:16Z</mods:dateAvailable>
   </mods:extension>
   <mods:extension>
      <mods:dateAccessioned encoding="iso8601">2024-01-19T18:07:16Z</mods:dateAccessioned>
   </mods:extension>
   <mods:originInfo>
      <mods:dateIssued encoding="iso8601">2023</mods:dateIssued>
   </mods:originInfo>
   <mods:identifier type="citation">Santamaría-Aguirre J, Jacho D, Méndez MA, Poveda A, Carrión J, Fanarraga ML. Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid. Pharmaceutics. 2024; 16(1):41. https://doi.org/10.3390/pharmaceutics16010041</mods:identifier>
   <mods:identifier type="doi">10.3390/pharmaceutics16010041</mods:identifier>
   <mods:identifier type="uri">https://hdl.handle.net/20.500.14352/94146</mods:identifier>
   <mods:identifier type="essn">1999-4923</mods:identifier>
   <mods:identifier type="officialurl">https://doi.org/10.3390/pharmaceutics16010041</mods:identifier>
   <mods:identifier type="relatedurl">https://www.mdpi.com/1999-4923/16/1/41</mods:identifier>
   <mods:abstract>Leishmaniasis, a zoonotic parasitic disease transmitted by infected sandflies, impacts nearly 1 million people yearly and is endemic in many countries across Asia, Africa, the Americas, and the Mediterranean; despite this, it remains a neglected disease with limited effective treatments, particularly in impoverished communities with limited access to healthcare. This study aims to repurpose approved drugs for an affordable leishmaniasis treatment. After the screening of potential drug candidates by reviewing databases and utilizing molecular docking analysis, delamanid was chosen to be incorporated into solid lipid nanoparticles (SLNPs). Both in cellulo and in vivo tests confirmed the successful payload release within macrophages and through the epidermis following topical application on murine skin. The evaluation of macrophages infected with L. infantum amastigotes showed that the encapsulated delamanid exhibited greater leishmanicidal activity compared with the free drug. The process of encapsulating delamanid in SLNPs, as demonstrated in this study, places a strong emphasis on employing minimal technology, ensuring energy efficiency, cost-effectiveness, and reproducibility. It enables consistent, low-cost production of nanomedicines, even on a small scale, offering a promising step toward more accessible and effective leishmaniasis treatments.</mods:abstract>
   <mods:language>
      <mods:languageTerm>eng</mods:languageTerm>
   </mods:language>
   <mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
   <mods:accessCondition type="useAndReproduction">open access</mods:accessCondition>
   <mods:accessCondition type="useAndReproduction">Attribution 4.0 International</mods:accessCondition>
   <mods:titleInfo>
      <mods:title>Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid</mods:title>
   </mods:titleInfo>
   <mods:genre>journal article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>